Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

CEO Rob Davis referred to the cost reduction program as a “reallocation” rather than a cut, with the savings to be reinvested ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

While some analysts forecasted the tariffs could mean billions in additional industry expenditure, others expect the overall ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The swift FDA action removes an overhang from Sarepta and allows Elevidys to return to the market without another safety ...

Six weeks after HHS Secretary RFK Jr. cited unexplained conflicts of interest in dismissing all 17 members of the CDC’s vaccine advisory committee, Democrats are asking for details.

The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

The Commissioner’s National Priority Vouchers aim to offer accelerated pathways to drugs that meet certain criteria, perhaps ...

Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...

Despite the failure of its Recognify-partnered inidascamine, Jefferies analysts do not expect a definitively negative stock ...